Short Communication

Bedaquiline metabolism: enzymes and novel metabolites

Ke Liu, Feng Li, Jie Lu, Shinlan Liu, Kenneth Dorko, Wen Xie, Xiaochao Ma

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy,

University of Pittsburgh, Pittsburgh, Pennsylvania (K.L., J.L. S.L., W.X., X.M.); Department of

Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City,

Kansas (F.L., K.D.)

DMD Fast Forward. Published on February 10, 2014 as DOI: 10.1124/dmd.113.056119 This article has not been copyedited and formatted. The final version may differ from this version.

DMD #056119

Running title: Bedaquiline metabolism

Corresponding author: Xiaochao Ma, Ph.D., Center for Pharmacogenetics, Department of

Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA 15261.

Tel. (412) 648-9448, E-mail: mxiaocha@pitt.edu

Number of Text Pages: 16

Number of Table: 0

Number of Figures: 2

Number of References: 18

Number of Words in the Abstract: 127

Number of Words in the Introduction: 660

Number of Words in the Results and Discussion: 704

Abbreviations: BDQ, bedaquiline; MDR-TB, multi-drug resistant tuberculosis; P450, cytochrome P450; UPLC-QTOFMS, ultra performance liquid chromatography coupled to time-of-flight mass spectrometry; OPLS-DA, orthogonal partial least-squares discriminant analysis

Abstract

Bedaquiline is a recently approved drug for treatment of multi-drug resistant tuberculosis. Adverse cardiac and hepatic drug reactions of bedaquiline have been noted in clinical practice. The current study investigated bedaquiline metabolism in human hepatocytes using a metabolomic approach. Bedaquiline *N*-demethylation *via* cytochrome P450 3A4 (CYP3A4) was confirmed as the major pathway in bedaquiline metabolism. Besides CYP3A4, we found that both CYP2C8 and CYP2C19 contributed to bedaquiline *N*-demethylation. The K_m values of CYP2C8, CYP2C19 and CYP3A4 in bedaquiline *N*-demethylation were 13.1, 21.3 and 8.5 µM, respectively. We also identified a novel metabolic pathway of bedaquiline that produced an aldehyde intermediate. In summary, this study extended our knowledge of bedaquiline metabolism, which can be applied to predict and prevent drug-drug interactions and adverse drug reactions associated with bedaquiline.

Introduction

Multi-drug resistant tuberculosis (MDR-TB) is defined as tuberculosis (TB) with resistance to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs (Chang and Yew, 2013). There were ~0.31 million incident cases of MDR-TB among TB patients in 2011. Treatment of MDR-TB requires second line anti-TB agents given over a period of 18-24 months (Mukherjee et al., 2004). Significant side effects and high patient death rate were observed during the long-term treatment against MDR-TB (WHO, 2013). Thus, there is an urgent need to develop shorter and less toxic regimen to reduce the side effects and mortality associated with MDR-TB chemotherapy.

Bedaquiline (BDQ) was recently approved by the United States Food and Drug Administration for the treatment of MDR-TB (FDA, 2012b). BDQ is a diarylquinoline with a novel mechanism of action specifically inhibiting mycobacterial ATP synthase (Cole and Alzari, 2005). In a randomized phase 2 placebo-controlled clinical trial among patients with MDR-TB, 48% of patients received BDQ in combination with standard MDR regimen showed conversion to negative culture in 8 weeks, compared with 9% in the placebo group that received the standard MDR regimen (Diacon et al., 2009). After 24 weeks, the proportion of patients that reached treatment success was 78.8% in BDQ group and 57.6% in placebo group (Diacon et al., 2012). However, BDQ carries a boxed warning indicating that this drug can cause QT prolongation, which could lead to an abnormal and potentially fatal heart rhythm (FDA, 2012a). In addition, the rate of drug-related hepatic disorders of BDQ group (8.8%) was higher than that of placebo group (1.9%) (FDA, 2012a).

4

Illustration of BDQ metabolism will provide valuable information to predict and prevent drugdrug interactions and adverse drug reactions associated with BDQ. CYP3A4 is involved in BDQ metabolism, leading to the formation of a dominant but less active *N*-desmethyl metabolite (Janssen Pharmacutical Companies, 2012). BDQ and its metabolites, including *N*-desmethyl BDQ, *N*-didesmethyl BDQ and two hydroxyl metabolites, are mainly excreted via feces (Cuyckens et al., 2008; Meermann et al., 2012). However, limited information is available for bioactivation pathways of BDQ that may be related to BDQ toxicity. In addition, it is unknown whether CYP3A4 is the only P450 that contributes to BDQ metabolism. The current study was designed to explore novel metabolic pathways of BDQ metabolism using a metabolomic approach. The involvement of P450s in BDQ *N*-demethylation, the dominant pathway in BDQ metabolism, was also investigated using recombinant P450s. We identified a novel pathway in BDQ metabolism, which produces an aldehyde intermediate. We also found that CYP2C8 and 2C19, together with CYP3A4, are involved in BDQ *N*-demethylation.

Material and Method

Chemicals. BDQ was purchased from Adooq Bioscience (Irvine, CA). Hepatocyte maintenance medium, dexamethasone and insulin were obtained from Lonza (Walkersville, MD). Penicillin G/Streptomycin and amphotericin B were obtained from GIBCO Laboratories (Grand Island, NY). Type I (rat-tail) collagen was purchased from BD Biosciences (Bedford, MA). The recombinant human P450s and human liver microsomes were purchased from XenoTech, LLC (Lenexa, KS). Formic acid, β -Nicotinamide adenine dinucleotide 2'-phosphate reduced tetrasodium salt hydrate (NADPH), dimethyl sulfoxide (DMSO), ethyl acetate (EtOAc) and methoxylamine (MeONH₂) were obtained from Sigma Aldrich (St Louis, MO).

BDQ metabolism in human hepatocytes. Fresh isolated human hepatocytes were plated at a cell density of 0.5×10^6 cells/well in 12-well plates previously coated with 0.2 mg/ml type I collagen. The isolated hepatocytes (> 80% viability) were maintained in human maintenance medium supplemented with 100 nM dexamethasone, 100 nM insulin, 100 U/ml penicillin G, 100 μ g/ml streptomycin and 10% bovine calf serum and kept at 37°C in a humidified incubator with 95% air/5% CO₂. The hepatocytes were allowed to attach to the plate for 4 hours then the media was replaced with serum-free human maintenance medium. For the metabolism study, human hepatocytes were lysed by adding 200 μ l of acetonitrile: H₂O (1:1, ν/ν). Both medium and hepatocytes lysates were extracted by adding 4 fold volume of EtOAc. The mixture was then vortexed for 1 min and centrifuged at 15,000 g for 10 min. The organic phase was transferred to a glass tube and dried under a gentle stream of nitrogen. The residue was reconstituted by 100 μ l of acetonitrile: H₂O (1:1, ν/ν). Five μ l of the solution was injected onto a system combining ultra

performance liquid chromatography and time-of-flight mass spectrometry (UPLC-QTOFMS) for metabolite analysis.

BDQ metabolism in recombinant P450s and human liver microsomes. Incubations were carried out in 1×phosphate-buffered saline (pH 7.4), containing cDNA-expressed P450 isozymes and 30 μ M BDQ with or without 5 mM of the aldehyde trapping reagent MeONH₂ in a final volume of 190 μ l. The reactions were initiated by adding 10 μ l of 20 mM NADPH and continued for 20 min with gentle shaking. The kinetics of *N*-desmethyl BDQ formation by c-DNA expressed P450s were determined by incubating BDQ at different concentrations up to 100 μ M. Incubations were also carried out in human liver microsomes and in presence of MeONH₂ (5 mM) to trap aldehyde metabolite of BDQ.

UPLC-QTOFMS analysis. Chromatographic separation of BDQ metabolites was performed on an Acquity UPLC BEH C18 column (2.1×100 mm, 1.7μ m, Waters). The flow rate of the mobile phase was 0.40 ml/min and the column temperature was maintained at 50 °C. QTOFMS was operated in positive mode with electrospray ionization. The source and desolvation temperatures were set at 120 and 350 °C, respectively. Nitrogen was applied as the cone gas (10 l/h) and desolvation gas (700 l/h). Argon was applied as the collision gas. The capillary and cone voltages were set at 3.5 kV and 35 V. QTOFMS was calibrated with sodium formate and monitored by the intermittent injection of lock mass leucine enkephalin in real time. Screening and identification of BDQ metabolites were performed by using MarkerLynx software (Waters) based on accurate mass measurement (mass errors less than 10 ppm). Product ion scans with

collision energy ramping from 15 to 45 V were used for structural elucidations of BDQ and its metabolites.

Data analysis. Mass spectra were acquired by MassLynx 4.1 in centroid format from m/z 50 to 1000. Centroid and integrated mass chromatographic data were processed by Markerlynx software to generate a multivariate data matrix. These data were imported to EZinfo software (Umetrics) for orthogonal partial least-squares discriminant analysis (OPLS-DA) on Pareto-scaled data. The corresponding data matrices were then exported in to SIMCA-P+ (Version 13, Umetrics) for multivariate data analysis.

DMD Fast Forward. Published on February 10, 2014 as DOI: 10.1124/dmd.113.056119 This article has not been copyedited and formatted. The final version may differ from this version.

DMD #056119

Results and Discussion

Profiling of BDQ metabolites in human hepatocytes. Metabolomics has proved to be a powerful tool for profiling drug metabolism and bioactivation pathways (Ma et al., 2008; Li et al., 2011). In the current study, an UPLC-QTOFMS-based metabolomic approach was used to profile BDQ metabolism. The results of chemometric analysis on the ions produced by UPLC-QTOFMS assay of control and BDQ treated human hepatocytes are shown in Supplemental Fig.1. The OPLS-DA analysis revealed two clearly separated clusters corresponding to control and BDQ treated groups (Supplemental Fig. 1A). The corresponding S-plot displays ions contributing to the group separation (Supplemental Fig. 1B). The top ranking ions were identified as BDQ metabolites (Fig. 1 and Supplemental Figs. 3-4) based on mass defect shifts and bromide isotopic pattern. Overall, 8 metabolites were identified in human hepatocytes, including 6 previously reported metabolites (M1, M2, M3, M4, M7 and M8) and 2 novel metabolites (M5 and M6). All BDQ metabolites identified in human hepatocytes were also found in the feces of mice treated with BDQ (data not shown). The BDQ metabolites are summarized in Supplemental Table 1.

Identification of novel BDQ metabolites. M6 was found as a novel BDQ metabolite during metabolomic analysis (Supplemental Fig. 1). The retention time of M6 was 8.90 min with protonated ions $[M + H]^+$ at m/z = 542 and 544 in a nearly 1: 1 ratio because of the ⁷⁹Br/⁸¹Br isotopic pattern (Fig. 1). The MS/MS spectrum of M6 showed major fragment ions at m/z 327/329, 310/312, 236/238 and 91 (Fig. 1B and 1C). Compared with the MS/MS spectrum of BDQ (Supplemental Fig. 2), the absence of ions at m/z 58, 229 suggest that the dimethylamino

moiety has been removed. M6 was proposed as a carboxylic acid metabolite (Fig. 1A). In theory, M6 is an oxidized product of an aldehyde, which can be generated in *N*-dealkylation of BDQ. The aldehyde intermediate M5 was confirmed in the incubations with human liver microsomes. MeONH₂ was used as a trapping agent that produced M5-oxime as a stable adduct (Fig. 1D). M5-oxime was eluted at 9.52 min with protonated ions $[M + H]^+$ at m/z = 555 and 557. Compared with fragment ions of M6 (Fig. 1B and 1C), these same ions were observed in MS/MS analysis of M5-oxime, including m/z 327/329, 310/312, 236/238, 91 (Fig. 1E and 1F). These results suggest that BDQ *N*-dealkylation occurred and produced an aldehyde (M5) (Fig. 1G). Further studies demonstrated that M5 formation is primarily mediated by CYP3A4 (Supplement Fig.5). In general, production of an aldehyde is considered as an unwanted pathway in drug metabolism because aldehydes are more reactive and they may lead to toxicity (Uchida, 2000; O'Brien et al., 2005). Thus, this study provides a clue to investigate adverse drug reactions associated with BDQ in relation to BDQ *N*-dealkylation.

Role of P450s in BDQ *N*-Demethylation. When BDQ is metabolized, *N*-demethylation is the major metabolic pathway and *N*-desmethyl BDQ (M1) is the main circulating metabolite (FDA, 2012a). Compared with BDQ, M1 has a three to six-fold lower anti-mycobacterial activity. However, M1 is more cytotoxic and a stronger inducer of phospholipidosis than BDQ (Mesens et al., 2007). Formation of M1 is mediated primarily by CYP3A4 (Janssen Pharmacutical Companies, 2012). We found that CYP2C8 and CYP2C19 are also involved in BDQ *N*-demethylation (Fig. 2A). The K_m values of CYP2C8, CYP2C19 and CYP3A4 in M1 formation were 13.1, 21.3 and 8.5 μ M, respectively (Fig. 2B). These results indicate that CYP3A4 is not the only enzyme in BDQ *N*-demethylation. Thus, when patients receive BDQ together with

drugs that are CYP3A4 inhibitors, BDQ *N*-demethylation may not be completely blocked, because CYP2C8 and CYP2C19 also contribute to BDQ *N*-demethylation. However, when patients receive BDQ together with drugs that are CYP3A4 inducers, such as ligands of pregnane X receptor, BDQ *N*-demethylation may be extremely accelerated because activation of pregnane X receptor induces the expression of CYP2C8, CYP2C19 and CYP3A4 (Gerbal-Chaloin et al., 2001; Luo et al., 2002).

In summary, BDQ metabolism was investigated in human hepatocytes by using a metabolomics approach. BDQ *N*-dealkylation was identified as a novel metabolic pathway of BDQ that produces an aldehyde intermediate. CYP2C8 and CYP2C19, together with CYP3A4, were involved in BDQ *N*-demethylation. These results can be applied to predict and prevent drug-drug interactions and adverse drug reactions associated with BDQ.

DMD Fast Forward. Published on February 10, 2014 as DOI: 10.1124/dmd.113.056119 This article has not been copyedited and formatted. The final version may differ from this version.

DMD #056119

Authorship contributions

Participated in research design: Liu, Li and Ma

Conducted experiments: Liu, Lu and Liu S.

Contributed the new reagents or analytic tools: Liu, Li, Dorko and Xie

Performed data analysis: Liu and Ma

Wrote or contributed to the writing of manuscript: Liu and Ma

Reference

Chang KC and Yew WW (2013) Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. *Respirology* **18**:8-21.

Cole ST and Alzari PM (2005) Microbiology. TB--a new target, a new drug. *Science* **307:**214-215.

Companies JP (2012) Briefing Document, TMC207 (bedaquiline), Treatment of Patients with MDR-TB, NDA 204-384.

Cuyckens F, Balcaen LI, De Wolf K, De Samber B, Van Looveren C, Hurkmans R, and Vanhaecke F (2008) Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS analysis of a new drug in development. *Anal Bioanal Chem* **390**:1717-1729.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, and McNeeley DF (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. *Antimicrob Agents Chemother* **56**:3271-3276.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, and Mc Neeley DF (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* **360**:2397-2405. FDA (2012a) Briefing Package: NDA 204-384: Sirturo.

FDA (2012b) FDA approves first drug to treat multidrug-resistant tuberculosis.

Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary culture. *Drug metabolism and disposition: the biological fate of chemicals* **29**:242-251.

Li F, Lu J, Wang L, and Ma X (2011) CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism. *Drug metabolism and disposition: the biological fate of chemicals* **39:**394-401.

Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, and Gan LS (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. *Drug metabolism and disposition: the biological fate of chemicals* **30**:795-804.

Ma X, Chen C, Krausz KW, Idle JR, and Gonzalez FJ (2008) A metabolomic perspective of melatonin metabolism in the mouse. *Endocrinology* **149**:1869-1879.

Meermann B, Bockx M, Laenen A, Van Looveren C, Cuyckens F, and Vanhaecke F (2012) Speciation analysis of bromine-containing drug metabolites in feces samples from a human in vivo study by means of HPLC/ICP-MS combined with on-line isotope dilution. *Anal Bioanal Chem* **402**:439-448.

Mesens N, Verbeeck J, and Rouan M (2007) Elucidating the role of M2 in the preclinical safety profile of TMC207. *38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease*.

Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, Furin JJ, Becerra MC, Barry DJ, Kim JY, Bayona J, Farmer P, Smith Fawzi MC, and Seung KJ (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. *Lancet* **363**:474-481.

O'Brien PJ, Siraki AG, and Shangari N (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. *Critical reviews in toxicology* **35:**609-662.

Uchida K (2000) Role of reactive aldehyde in cardiovascular diseases. *Free radical biology & medicine* **28**:1685-1696.

WHO (2013) The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance.

Footnotes

This work was supported in part by the National Institute of Diabetes and Digestive and Kidney

Diseases [DK090305] and the National Institute of Allergy and Infectious Diseases [AI095425].

DMD Fast Forward. Published on February 10, 2014 as DOI: 10.1124/dmd.113.056119 This article has not been copyedited and formatted. The final version may differ from this version.

DMD #056119

Figure legends

Figure 1. BDQ *N*-dealkylation and formation of an aldehyde and a carboxylic acid metabolite. (A-C) Identification of a carboxylic acid metabolite of BDQ (M6) in human hepatocytes. (A) Extracted ion chromatograph of M6. (B) and (C) MS/MS spectrum of M6 at m/z 542 and 544. (D-F) Trapping of aldehyde (M5) intermediate in BDQ metabolism in human liver microsomes. MeONH₂ was used as a trapping agent. (D) Extracted ion chromatograph of M5-oxime. (E) and (F) MS/MS spectrum of M5-oxime at m/z 555 and 557. (G) Proposed mechanism for the formation of aldehyde (M5) and carboxylic metabolite (M6) in BDQ metabolism.

Figure 2. Role of P450s in BDQ *N*-demethylation (M1). cDNA expressed P450s were used to determine the contribution of individual P450s in M1 formation. The incubation conditions were detailed in the experimental procedures and M1 was determined by UPLC-QTOFMS. (A) Relative contribution of P450s in M1 formation. The data are expressed as mean \pm SD (n=3). The data in CYP3A4 group was set as 100%. (B) Enzymatic kinetics of CYP2C8, 2C19 and 3A4 in M1 formation.

Figure 1





Figure 2



Supplemental data

(Short Communication)

Bedaquiline metabolism: enzymes and novel metabolites

Ke Liu, Feng Li, Jie Lu, Shinlan Liu, Kenneth Dorko, Wen Xie, Xiaochao Ma

Supplemental Figure 1. Metabolomics analysis of human hepatocytes treated with BDQ.


Supplemental Table 1. Summary of BDQ metabolites in human hepatocytes.

Supplemental Figure 2. Extracted ion chromatograph and MS/MS spectrum of BDQ.

Supplemental Figure 3. Identification of *N*-desmethyl BDQ (M1).

Supplemental Figure 4. Identification of M7.

Supplemental Figure 5. Role of P450s in formation of BDQ aldehyde (M5).




Supplemental Figure 1. Metabolomics analysis of human hepatocytes treated with BDQ. Human hepatocytes were treated with 30 μ M of BDQ for 18 h. The cell lysates were collected and analyzed by UPLC-QTOFMS. (A) Separation of control and BDQ-treated human hepatocytes in an OPLS-DA scores plot. t[1]P and t[2]O represent the score of each sample in principal component 1 and 2, respectively. (B) Loading S-plot generated by OPLS-DA analysis. The *x*-axis represents the relative abundance of ions, and *y*-axis is a measure of the correlation of each ion to the model. The top ranking ions are labeled. BDQ was excluded from the S-plot during data analysis.

Supplemental Table 1. Summary of BDQ metabolites in human hepatocytes.


Human hepatocytes were treated with 30 µM of BDQ for 18 h. The cell lysates were collected and analyzed by UPLC-QTOFMS. Screening and identification of BDQ metabolites were performed by using MarkerLynx software (Waters) based on accurate mass measurement (mass errors less than 10 ppm).

Metabolite	m/z	RT (min)	Predicted Formula	Mass Error (ppm)	Identification
MO	555.1639	6.64	C ₃₂ H ₃₁ BrN ₂ O ₂	-0.5	Parent (BDQ)
M1	541.1498	6.56	C ₃₁ H ₂₉ BrN ₂ O ₂	2.4	N-desmethyl BDQ
M2	527.1336	6.50	C ₃₀ H ₂₇ BrN ₂ O ₂	1.3	N-didesmethyl BDQ
M3	571.1619	6.70	C ₃₂ H ₃₁ BrN ₂ O ₃	4.9	O_BDQ_1
M4	571.1598	6.22	C ₃₂ H ₃₁ BrN ₂ O ₃	1.2	O_BDQ_2
M5-oxime	555.1279	9.59	C ₃₁ H ₂₇ BrN ₂ O ₃	0.2	BDQ_aldehyde_MeONH 2
M6	542.0983	8.90	C ₃₀ H ₂₄ BrNO4	4.1	Carboxylic acid metabolite
M7	482.0742	9.77	C ₂₈ H ₂₀ BrNO2	-1.7	Keto metabolite
M8	557.1466	6.17	C ₃₁ H ₂₉ BrN ₂ O ₃	5.7	N-desmethyl O_BDQ


RT: retention time; O, monohydroxylated.




Supplemental Figure 2. Extracted ion chromatograph (A) and MS/MS spectrum (B and C) of BDQ at m/z 555 and 557.



Supplemental Figure 3. Identification of *N*-desmethyl BDQ (M1). (A) Extracted ion chromatograph of M1. (B) and (C) MS/MS spectrum of M1 at m/z 541 and 543.



Supplemental Figure 4. Identification of M7. (A) Extracted ion chromatograph of M7. (B) and (C) MS/MS spectrum of M7 at m/z 482 and 484.



Supplemental Figure 5. Role of P450s in formation of BDQ aldehyde (M5). cDNA-expressed P450s were used to determine the contribution of individual P450s in M5 formation and MeONH₂ was used as the trapping reagent. The incubation conditions were detailed in the experimental procedures and M5-oxime was determined by UPLC-QTOFMS. The data are expressed as mean (n=2). The data in control group was set as 1.